AR022583A1 - Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos - Google Patents
Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidosInfo
- Publication number
- AR022583A1 AR022583A1 ARP000100613A ARP000100613A AR022583A1 AR 022583 A1 AR022583 A1 AR 022583A1 AR P000100613 A ARP000100613 A AR P000100613A AR P000100613 A ARP000100613 A AR P000100613A AR 022583 A1 AR022583 A1 AR 022583A1
- Authority
- AR
- Argentina
- Prior art keywords
- ribonucleotid
- antitumoral
- sense
- reduction
- directed against
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos y métodos para modular la proliferacion celular, con preferencia, para inhibir la proliferacion de células tumorales. Loscompuestos que pueden emplearse para modular la proliferacion celular incluyen los oligonucleotidosantis entido complementarios con las regiones de los genesde la reductasa de los ribonucleotidos de los mamíferos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/249,730 US6121000A (en) | 1999-02-11 | 1999-02-11 | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
Publications (1)
Publication Number | Publication Date |
---|---|
AR022583A1 true AR022583A1 (es) | 2002-09-04 |
Family
ID=22944744
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100613A AR022583A1 (es) | 1999-02-11 | 2000-02-11 | Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos |
Country Status (17)
Country | Link |
---|---|
US (1) | US6121000A (es) |
EP (1) | EP1153128B8 (es) |
JP (1) | JP4424857B2 (es) |
KR (1) | KR20020013501A (es) |
CN (1) | CN1345373A (es) |
AR (1) | AR022583A1 (es) |
AT (1) | ATE309346T1 (es) |
AU (1) | AU780455B2 (es) |
BR (1) | BR0008788A (es) |
CA (1) | CA2366487A1 (es) |
DE (1) | DE60023845T2 (es) |
ES (1) | ES2259602T3 (es) |
IL (1) | IL144727A0 (es) |
MX (1) | MXPA01008137A (es) |
NZ (1) | NZ514090A (es) |
RU (1) | RU2001124840A (es) |
WO (1) | WO2000047733A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6593305B1 (en) * | 1996-08-02 | 2003-07-15 | Genesense Technologies Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
MXPA04010282A (es) * | 2002-04-18 | 2005-08-18 | Acuity Pharmaceuticals Inc | Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo. |
US7148342B2 (en) | 2002-07-24 | 2006-12-12 | The Trustees Of The University Of Pennyslvania | Compositions and methods for sirna inhibition of angiogenesis |
AU2004209579B2 (en) * | 2003-02-10 | 2010-03-04 | Lorus Therapeutics Inc. | Antisense oligonucleotides directed to ribonucleotide reductase R2 and uses thereof in the treatment of cancer |
AU2004233043A1 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for siRNA inhibition of angiopoietin 1 and 2 and their receptor Tie2 |
CN2734483Y (zh) * | 2003-05-02 | 2005-10-19 | 精工爱普生株式会社 | 打印机 |
US20070274947A1 (en) * | 2003-05-21 | 2007-11-29 | Young Aiping H | Antisense Oligonucleotides Directed to Ribonucleotide Reductase R1 and Uses Thereof in the Treatment of Cancer |
WO2004106518A1 (en) * | 2003-05-31 | 2004-12-09 | Genesense Technologies Inc. | Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer |
US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
EP1715896A4 (en) * | 2004-01-12 | 2009-01-07 | Lorus Therapeutics Inc | ANTISENSE OLIGONUCLEOTIDES AGAINST RIBONUCLEOTIDE REDUCTASE R2 AND ITS USE IN COMBINATION THERAPIES FOR THE TREATMENT OF CANCER |
US8029815B2 (en) * | 2004-04-28 | 2011-10-04 | Elford Howard L | Methods for treating or preventing restenosis and other vascular proliferative disorders |
WO2006017932A1 (en) * | 2004-08-18 | 2006-02-23 | Genesense Technologies Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
WO2007133758A1 (en) * | 2006-05-15 | 2007-11-22 | Physical Pharmaceutica, Llc | Composition and improved method for preparation of small particles |
ES2390499T3 (es) * | 2006-06-12 | 2012-11-13 | Opko Pharmaceuticals, Llc | Composiciones y métodos para la inhibición de la angiogénesis por sirna |
US7872118B2 (en) * | 2006-09-08 | 2011-01-18 | Opko Ophthalmics, Llc | siRNA and methods of manufacture |
US20080305157A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Maryland Office Of Technology Commercialization | Encapsulation and separation of charged organic solutes inside catanionic vesicles |
EP2030615A3 (en) * | 2007-08-13 | 2009-12-02 | ELFORD, Howard L. | Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases |
US20100204305A1 (en) * | 2007-12-11 | 2010-08-12 | Lorus Therapeutics Inc. | Small interfering rna molecules against ribonucleotide reductase and uses thereof |
EP2361306A1 (en) | 2008-12-04 | 2011-08-31 | OPKO Ophthalmics, LLC | Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms |
DE102019000490A1 (de) * | 2019-01-23 | 2020-07-23 | HAEMES Verwaltungsgesellschaft mbH | Verwendung von Oligonukleotiden für die Behandlung von Tumoren |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5225347A (en) * | 1989-09-25 | 1993-07-06 | Innovir Laboratories, Inc. | Therapeutic ribozyme compositions and expression vectors |
US5766855A (en) * | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
WO1994021661A1 (en) * | 1993-03-23 | 1994-09-29 | The Board Of Trustees Of The Leland Stanford Junior University | Cellular regulation with riboregulators |
ATE309345T1 (de) * | 1996-08-02 | 2005-11-15 | Genesense Technologies Inc | Antitumor antisense sequenzen gegen h1 und r2 verbindungen von ribonukleotide reductase |
-
1999
- 1999-02-11 US US09/249,730 patent/US6121000A/en not_active Expired - Fee Related
-
2000
- 2000-02-09 KR KR1020017010204A patent/KR20020013501A/ko not_active Application Discontinuation
- 2000-02-09 EP EP00903456A patent/EP1153128B8/en not_active Expired - Lifetime
- 2000-02-09 WO PCT/CA2000/000120 patent/WO2000047733A1/en active IP Right Grant
- 2000-02-09 AT AT00903456T patent/ATE309346T1/de not_active IP Right Cessation
- 2000-02-09 CN CN00805667A patent/CN1345373A/zh active Pending
- 2000-02-09 NZ NZ514090A patent/NZ514090A/en not_active IP Right Cessation
- 2000-02-09 BR BR0008788-2A patent/BR0008788A/pt not_active Application Discontinuation
- 2000-02-09 DE DE60023845T patent/DE60023845T2/de not_active Expired - Lifetime
- 2000-02-09 ES ES00903456T patent/ES2259602T3/es not_active Expired - Lifetime
- 2000-02-09 MX MXPA01008137A patent/MXPA01008137A/es not_active Application Discontinuation
- 2000-02-09 CA CA002366487A patent/CA2366487A1/en not_active Abandoned
- 2000-02-09 JP JP2000598631A patent/JP4424857B2/ja not_active Expired - Fee Related
- 2000-02-09 IL IL14472700A patent/IL144727A0/xx unknown
- 2000-02-09 AU AU25292/00A patent/AU780455B2/en not_active Ceased
- 2000-02-09 RU RU2001124840/15A patent/RU2001124840A/ru unknown
- 2000-02-11 AR ARP000100613A patent/AR022583A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IL144727A0 (en) | 2002-06-30 |
EP1153128A1 (en) | 2001-11-14 |
EP1153128B1 (en) | 2005-11-09 |
ES2259602T3 (es) | 2006-10-16 |
AU780455B2 (en) | 2005-03-24 |
DE60023845D1 (de) | 2005-12-15 |
EP1153128B8 (en) | 2006-01-18 |
AU2529200A (en) | 2000-08-29 |
KR20020013501A (ko) | 2002-02-20 |
NZ514090A (en) | 2005-01-28 |
ATE309346T1 (de) | 2005-11-15 |
RU2001124840A (ru) | 2004-03-27 |
JP4424857B2 (ja) | 2010-03-03 |
DE60023845T2 (de) | 2006-08-10 |
MXPA01008137A (es) | 2004-08-12 |
BR0008788A (pt) | 2001-11-06 |
WO2000047733A1 (en) | 2000-08-17 |
CA2366487A1 (en) | 2000-08-17 |
JP2003500006A (ja) | 2003-01-07 |
CN1345373A (zh) | 2002-04-17 |
US6121000A (en) | 2000-09-19 |
WO2000047733A9 (en) | 2001-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR022583A1 (es) | Secuencias antitumorales anti-sentido dirigidas contra los componentes r1 y r2 de la reductasa de los ribonucleotidos | |
CA2262776A1 (en) | Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase | |
EA200500206A1 (ru) | СПОСОБ И КОМПОЗИЦИИ ДЛЯ МОДУЛЯЦИИ РАЗВИТИЯ И ФУНКЦИИ КЛЕТОК Т-ХЕЛПЕРОВ (Тх) | |
ATE382681T1 (de) | Verbesserung der herzfunktion durch transplantation mesenchymaler stammzellen | |
NO20001583D0 (no) | Stimulering av hematopoetiske celler in vitro | |
AU1116400A (en) | A method of inducing or enhancing chondrogenesis with extracellular matrix containing gdf-5 | |
ATE250571T1 (de) | Kaliumkanal-blocker | |
TR200103216T2 (tr) | Pirimidinon bileşimleri | |
ATA165999A (de) | Medium zur protein- und serumfreien kultivierung von zellen | |
ATE265426T1 (de) | Kaliumkanalblocker | |
DK1117672T3 (da) | Antisense-modulation af survivin-ekpression | |
YU19499A (sh) | Benzonaftiridini kao bronhijalni terapeutici | |
DE69630955D1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
PL336983A1 (en) | Compounds, their production and application as carriers of nucleic acids in cells | |
AU2904300A (en) | Polysubstituted 6-phenylphenanthridines with pde-iv inhibiting activity | |
BR0110087A (pt) | Compostos para modular proliferação celular | |
GB9825096D0 (en) | Cells,culture methods and their uses | |
DK1185621T3 (da) | Overflade til cellekultur | |
AU2606000A (en) | Antisense modulation of x-linked inhibitor of apoptosis expression | |
GB2379446A (en) | Cells,culture methods and their uses | |
DE69737597D1 (de) | Vektoren zur inhibierung von viralem und tumorwachstum | |
DK0925064T3 (da) | 5-Androsten-3-beta,17-alpha-diol som inhibitor for tumorvækst | |
DK1238057T3 (da) | Fremgangsmåde til produktion af vedhæftende dyreceller | |
PA8436101A1 (es) | Inhibidores de la actividad de la enzima naaladasa. | |
AU2139001A (en) | Modulation of PAX-2 for controlled apoptosis or survival of cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |